Get the latest tech news
OpenAI and the FDA Are Holding Talks About Using AI In Drug Evaluation
High-ranking OpenAI employees have met with the FDA multiple times in recent weeks to discuss AI and a project called cderGPT.
The remarks followed an annual meeting of the American Hospital Association earlier this week, where Makary spoke about AI’s potential to aid in the approval of new treatments for diabetes and certain types of cancer. But sources close to the project say a small team from OpenAI has met with the FDA and two associates of Elon Musk's so-called Department of Government Efficiency multiple times in recent weeks. When reached via email on Wednesday, Robert Califf, who served as FDA commissioner from 2016 to 2017 and again from 2022 through January, said the agency’s review teams have been using AI for several years now.
Or read this on Wired
